Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fentanyl | 7 | 2021 | 31 | 3.910 |
Why?
|
| Critical Illness | 14 | 2022 | 68 | 3.300 |
Why?
|
| Analgesics, Opioid | 10 | 2022 | 102 | 2.790 |
Why?
|
| Child | 34 | 2022 | 2144 | 2.370 |
Why?
|
| Hypnotics and Sedatives | 7 | 2022 | 29 | 2.160 |
Why?
|
| Substance Withdrawal Syndrome | 7 | 2017 | 39 | 1.940 |
Why?
|
| Methadone | 4 | 2019 | 17 | 1.880 |
Why?
|
| Opioid-Related Disorders | 5 | 2013 | 36 | 1.810 |
Why?
|
| Obesity | 6 | 2019 | 645 | 1.680 |
Why?
|
| Hydromorphone | 2 | 2021 | 7 | 1.520 |
Why?
|
| Child, Preschool | 19 | 2021 | 1084 | 1.510 |
Why?
|
| Neonatal Abstinence Syndrome | 3 | 2019 | 10 | 1.500 |
Why?
|
| Anti-Bacterial Agents | 8 | 2022 | 496 | 1.490 |
Why?
|
| Pediatrics | 4 | 2022 | 86 | 1.450 |
Why?
|
| Infant | 18 | 2022 | 960 | 1.400 |
Why?
|
| Hyponatremia | 3 | 2021 | 16 | 1.390 |
Why?
|
| Ketamine | 2 | 2022 | 9 | 1.320 |
Why?
|
| Retrospective Studies | 20 | 2022 | 2436 | 1.310 |
Why?
|
| Analgesics | 5 | 2016 | 34 | 1.300 |
Why?
|
| Education, Pharmacy, Graduate | 3 | 2022 | 17 | 1.280 |
Why?
|
| Humans | 56 | 2022 | 26755 | 1.260 |
Why?
|
| Postoperative Care | 3 | 2020 | 67 | 1.250 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2020 | 587 | 1.150 |
Why?
|
| Pharmacists | 4 | 2022 | 69 | 1.090 |
Why?
|
| Pharmaceutical Services | 3 | 2022 | 39 | 1.070 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2020 | 171 | 1.070 |
Why?
|
| Clonidine | 3 | 2016 | 10 | 1.000 |
Why?
|
| Pharmacy | 2 | 2022 | 33 | 0.990 |
Why?
|
| Adolescent | 15 | 2021 | 2949 | 0.990 |
Why?
|
| Anticoagulants | 3 | 2020 | 292 | 0.890 |
Why?
|
| Critical Care | 3 | 2022 | 50 | 0.830 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2019 | 10 | 0.760 |
Why?
|
| Education, Pharmacy | 3 | 2021 | 103 | 0.760 |
Why?
|
| Female | 23 | 2020 | 14408 | 0.750 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 3 | 2016 | 10 | 0.740 |
Why?
|
| Male | 23 | 2020 | 12824 | 0.730 |
Why?
|
| Liver Failure, Acute | 1 | 2020 | 4 | 0.730 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 3 | 0.720 |
Why?
|
| Antitubercular Agents | 1 | 2020 | 17 | 0.720 |
Why?
|
| Infant, Newborn | 12 | 2022 | 845 | 0.720 |
Why?
|
| Acetylcysteine | 1 | 2020 | 24 | 0.720 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2020 | 23 | 0.720 |
Why?
|
| Pharmacy Service, Hospital | 2 | 2019 | 14 | 0.700 |
Why?
|
| Drug Administration Schedule | 10 | 2017 | 218 | 0.700 |
Why?
|
| Warfarin | 1 | 2020 | 94 | 0.680 |
Why?
|
| Curriculum | 2 | 2019 | 257 | 0.680 |
Why?
|
| Internship and Residency | 1 | 2022 | 224 | 0.670 |
Why?
|
| Employment | 1 | 2019 | 45 | 0.670 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 18 | 0.670 |
Why?
|
| Career Choice | 1 | 2019 | 52 | 0.660 |
Why?
|
| Tobramycin | 2 | 2017 | 13 | 0.630 |
Why?
|
| Lorazepam | 2 | 2017 | 7 | 0.620 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 73 | 0.600 |
Why?
|
| Status Epilepticus | 1 | 2017 | 4 | 0.580 |
Why?
|
| Anesthetics, Intravenous | 1 | 2017 | 14 | 0.580 |
Why?
|
| Anticonvulsants | 1 | 2017 | 19 | 0.570 |
Why?
|
| Ceftazidime | 3 | 2022 | 15 | 0.570 |
Why?
|
| Patient Admission | 1 | 2016 | 28 | 0.540 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2016 | 4 | 0.530 |
Why?
|
| Arginine Vasopressin | 1 | 2016 | 8 | 0.530 |
Why?
|
| Vasoconstrictor Agents | 1 | 2016 | 34 | 0.530 |
Why?
|
| Shock | 1 | 2016 | 17 | 0.520 |
Why?
|
| Norwood Procedures | 1 | 2016 | 12 | 0.520 |
Why?
|
| Pain Management | 2 | 2015 | 52 | 0.520 |
Why?
|
| Morphine | 1 | 2015 | 28 | 0.510 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2015 | 8 | 0.510 |
Why?
|
| Vascular Diseases | 1 | 2016 | 67 | 0.500 |
Why?
|
| Scoliosis | 1 | 2015 | 34 | 0.490 |
Why?
|
| Pain, Postoperative | 1 | 2015 | 59 | 0.480 |
Why?
|
| Infusions, Intravenous | 6 | 2017 | 99 | 0.480 |
Why?
|
| Intensive Care Units, Neonatal | 5 | 2022 | 58 | 0.480 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 4 | 0.470 |
Why?
|
| Body Fluids | 1 | 2014 | 18 | 0.470 |
Why?
|
| Iatrogenic Disease | 2 | 2022 | 13 | 0.450 |
Why?
|
| Overweight | 2 | 2011 | 108 | 0.440 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2009 | 9 | 0.430 |
Why?
|
| Spinal Fusion | 1 | 2015 | 144 | 0.430 |
Why?
|
| Conscious Sedation | 1 | 2012 | 10 | 0.420 |
Why?
|
| Analgesia | 1 | 2012 | 12 | 0.420 |
Why?
|
| Nursing Assessment | 1 | 2012 | 27 | 0.420 |
Why?
|
| Immunoglobulin Fragments | 2 | 2010 | 6 | 0.410 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2021 | 27 | 0.410 |
Why?
|
| Antivenins | 2 | 2010 | 7 | 0.410 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2011 | 6 | 0.390 |
Why?
|
| Vancomycin | 1 | 2011 | 56 | 0.380 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 40 | 0.380 |
Why?
|
| Postoperative Complications | 1 | 2016 | 605 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 233 | 0.370 |
Why?
|
| Treatment Outcome | 5 | 2020 | 2262 | 0.360 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2009 | 9 | 0.350 |
Why?
|
| Snake Bites | 2 | 2010 | 6 | 0.350 |
Why?
|
| Narcotic Antagonists | 1 | 2009 | 31 | 0.340 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 26 | 0.340 |
Why?
|
| Viperidae | 1 | 2008 | 3 | 0.330 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 112 | 0.310 |
Why?
|
| Adult | 6 | 2020 | 7353 | 0.290 |
Why?
|
| Community-Acquired Infections | 1 | 2007 | 29 | 0.290 |
Why?
|
| Time Factors | 4 | 2017 | 1564 | 0.290 |
Why?
|
| Internship, Nonmedical | 1 | 2007 | 3 | 0.290 |
Why?
|
| Drug Tolerance | 2 | 2021 | 37 | 0.280 |
Why?
|
| Anti-Infective Agents | 3 | 2016 | 79 | 0.270 |
Why?
|
| Serum Albumin | 1 | 2006 | 35 | 0.270 |
Why?
|
| Blood Component Transfusion | 1 | 2006 | 13 | 0.270 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 77 | 0.270 |
Why?
|
| United States | 4 | 2019 | 2031 | 0.270 |
Why?
|
| Teaching | 1 | 2007 | 76 | 0.270 |
Why?
|
| Liver Transplantation | 1 | 2006 | 51 | 0.260 |
Why?
|
| Gram-Negative Bacteria | 3 | 2022 | 58 | 0.250 |
Why?
|
| Age Factors | 2 | 2019 | 713 | 0.240 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2004 | 35 | 0.240 |
Why?
|
| Thromboembolism | 1 | 2004 | 57 | 0.240 |
Why?
|
| Intensive Care Units | 2 | 2022 | 46 | 0.230 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 68 | 0.230 |
Why?
|
| Pilot Projects | 3 | 2012 | 386 | 0.230 |
Why?
|
| Pain Measurement | 2 | 2015 | 159 | 0.220 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2022 | 135 | 0.210 |
Why?
|
| Acute Kidney Injury | 2 | 2017 | 73 | 0.210 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 38 | 0.210 |
Why?
|
| Cephalosporins | 1 | 2022 | 18 | 0.200 |
Why?
|
| Linear Models | 2 | 2017 | 202 | 0.200 |
Why?
|
| Neuromuscular Blockade | 1 | 2022 | 8 | 0.200 |
Why?
|
| Delirium | 1 | 2022 | 13 | 0.200 |
Why?
|
| Cohort Studies | 2 | 2017 | 858 | 0.190 |
Why?
|
| Antidotes | 1 | 2020 | 2 | 0.180 |
Why?
|
| Problem-Based Learning | 1 | 2021 | 60 | 0.180 |
Why?
|
| Tuberculosis | 1 | 2020 | 23 | 0.180 |
Why?
|
| International Normalized Ratio | 1 | 2020 | 27 | 0.180 |
Why?
|
| Fontan Procedure | 1 | 2020 | 24 | 0.180 |
Why?
|
| Administration, Oral | 1 | 2020 | 166 | 0.180 |
Why?
|
| Metabolic Clearance Rate | 1 | 2019 | 18 | 0.170 |
Why?
|
| Furosemide | 1 | 2019 | 7 | 0.170 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 25 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 206 | 0.170 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 981 | 0.170 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 39 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2019 | 72 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 66 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2019 | 221 | 0.160 |
Why?
|
| Scholarly Communication | 1 | 2018 | 3 | 0.150 |
Why?
|
| Accreditation | 1 | 2018 | 33 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2019 | 382 | 0.150 |
Why?
|
| Program Development | 1 | 2018 | 74 | 0.150 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 34 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2017 | 34 | 0.150 |
Why?
|
| Hospitalization | 2 | 2017 | 192 | 0.150 |
Why?
|
| Oklahoma | 2 | 2018 | 968 | 0.150 |
Why?
|
| Administration, Rectal | 1 | 2017 | 5 | 0.150 |
Why?
|
| Diazepam | 1 | 2017 | 3 | 0.150 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 21 | 0.150 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 32 | 0.140 |
Why?
|
| Midazolam | 1 | 2017 | 8 | 0.140 |
Why?
|
| Catatonia | 1 | 2017 | 4 | 0.140 |
Why?
|
| Medical Errors | 1 | 2016 | 9 | 0.140 |
Why?
|
| Anti-HIV Agents | 1 | 2016 | 17 | 0.140 |
Why?
|
| Odds Ratio | 1 | 2017 | 231 | 0.140 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 14 | 0.140 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 15 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2016 | 42 | 0.130 |
Why?
|
| Inpatients | 1 | 2016 | 56 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 74 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 912 | 0.130 |
Why?
|
| Injections, Spinal | 1 | 2015 | 7 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 913 | 0.130 |
Why?
|
| Acetaminophen | 1 | 2015 | 11 | 0.130 |
Why?
|
| Aminoglycosides | 1 | 2014 | 10 | 0.120 |
Why?
|
| Pregnancy | 1 | 2019 | 1126 | 0.120 |
Why?
|
| Hyperphosphatemia | 1 | 2014 | 4 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 203 | 0.120 |
Why?
|
| HIV Infections | 1 | 2016 | 146 | 0.120 |
Why?
|
| Amphotericin B | 1 | 2014 | 17 | 0.120 |
Why?
|
| Antifungal Agents | 1 | 2014 | 58 | 0.110 |
Why?
|
| Language Development | 1 | 2013 | 4 | 0.110 |
Why?
|
| Opiate Substitution Treatment | 1 | 2013 | 5 | 0.110 |
Why?
|
| Alkalosis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2013 | 6 | 0.110 |
Why?
|
| Acetazolamide | 1 | 2013 | 9 | 0.110 |
Why?
|
| Motor Skills | 1 | 2013 | 32 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2014 | 220 | 0.110 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 7 | 0.110 |
Why?
|
| Bumetanide | 1 | 2012 | 2 | 0.110 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2010 | 20 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2012 | 28 | 0.100 |
Why?
|
| Anxiety | 1 | 2012 | 133 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 32 | 0.100 |
Why?
|
| Disease Management | 1 | 2012 | 84 | 0.090 |
Why?
|
| United Kingdom | 1 | 2011 | 70 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2012 | 96 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 748 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 297 | 0.090 |
Why?
|
| Enoxaparin | 1 | 2011 | 36 | 0.090 |
Why?
|
| Cognition | 1 | 2013 | 294 | 0.090 |
Why?
|
| Risk Factors | 3 | 2017 | 2012 | 0.090 |
Why?
|
| Logistic Models | 1 | 2011 | 397 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2010 | 18 | 0.090 |
Why?
|
| Dexmedetomidine | 1 | 2009 | 2 | 0.090 |
Why?
|
| Medication Errors | 1 | 2009 | 26 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2011 | 132 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 140 | 0.080 |
Why?
|
| Kentucky | 1 | 2007 | 4 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 7 | 0.070 |
Why?
|
| Otitis Media | 1 | 2007 | 35 | 0.070 |
Why?
|
| Documentation | 1 | 2007 | 24 | 0.070 |
Why?
|
| APACHE | 1 | 2006 | 4 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2007 | 111 | 0.070 |
Why?
|
| Morbidity | 1 | 2006 | 57 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2006 | 33 | 0.070 |
Why?
|
| Cross Infection | 1 | 2006 | 35 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2006 | 148 | 0.070 |
Why?
|
| Animals | 2 | 2009 | 9918 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2006 | 103 | 0.060 |
Why?
|
| Length of Stay | 1 | 2006 | 218 | 0.060 |
Why?
|
| Communication | 1 | 2007 | 166 | 0.060 |
Why?
|
| Creatine | 1 | 2004 | 32 | 0.060 |
Why?
|
| Incidence | 1 | 2006 | 545 | 0.060 |
Why?
|
| Monitoring, Physiologic | 1 | 2004 | 54 | 0.060 |
Why?
|
| Patient Selection | 1 | 2004 | 143 | 0.060 |
Why?
|
| Comorbidity | 1 | 2004 | 250 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 357 | 0.050 |
Why?
|
| Kidney | 1 | 2004 | 274 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 346 | 0.050 |
Why?
|
| Cefotaxime | 1 | 2022 | 5 | 0.050 |
Why?
|
| Monobactams | 1 | 2022 | 6 | 0.050 |
Why?
|
| Chlorothiazide | 1 | 2021 | 3 | 0.050 |
Why?
|
| Middle Aged | 2 | 2016 | 6791 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2022 | 84 | 0.050 |
Why?
|
| Sodium | 1 | 2021 | 47 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2021 | 111 | 0.050 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 21 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2022 | 328 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 252 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 25 | 0.030 |
Why?
|
| Aged | 1 | 2006 | 5153 | 0.030 |
Why?
|
| Amikacin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Gentamicins | 1 | 2014 | 15 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 38 | 0.030 |
Why?
|
| Phosphorus | 1 | 2014 | 51 | 0.030 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2013 | 23 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 209 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2013 | 133 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 400 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 58 | 0.020 |
Why?
|
| Crotalid Venoms | 1 | 2010 | 4 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 26 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2010 | 45 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 108 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 2575 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 44 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2007 | 264 | 0.020 |
Why?
|